Can nicotine gum (4 mg) or nicotine patches (21 mg) provide cardiovascular benefits or improve reaction time and motor performance in healthy nonsmokers?

Nicotine Gum and Patches Should NOT Be Used by Healthy Nonsmokers for Cardiovascular Benefits or Performance Enhancement

Nicotine replacement therapy (NRT) products including 4 mg gum and 21 mg patches are specifically designed and indicated for smoking cessation in current smokers, not for use by healthy nonsmokers seeking cardiovascular benefits or performance enhancement. The available guidelines explicitly state that NRT should be used by smokers attempting to quit, and there is no evidence supporting cardiovascular benefits in nonsmokers 1, 2.

Why This Recommendation Is Clear

Indication and Intended Use

The most recent Canadian Cardiovascular Society guideline (2025) and FDA labeling make it unequivocal that NRT is designed for smoking cessation only 2, 3. The FDA label specifically states these products are "Stop Smoking Aid" and "not for sale to those under 18 years of age" 3. All clinical guidelines from 1998 through 2025 consistently state: "NRT can be used by all smokers" attempting cessation, with no mention of use in nonsmokers for other purposes 1, 2.

Cardiovascular Effects in Nonsmokers Are Adverse, Not Beneficial

The physiological effects you describe are actually adverse cardiovascular responses, not benefits:

• Heart rate increases of 10-12% with 4 mg nicotine gum in nonsmokers represent sympathetic activation, not a therapeutic effect 4
• A 2011 study found 4 mg nicotine significantly decreased heart rate variability (HRV) in healthy nonsmokers, indicating reduced vagal activity and increased sympathetic tone—a marker of cardiovascular stress, not health 5
• A 2002 study showed nicotine gum increased afterload, cardiac output, and systemic vascular resistance in nonsmokers—these are hemodynamic stressors 6
• The 2026 review on snus and nicotine pouches confirms nicotine drives CVD risk through sympathetic activation, endothelial dysfunction, and increased arterial stiffness 7

No Performance Benefits in Nonsmokers

Research directly contradicts performance enhancement claims:

• A 1993 study found nicotine in nonsmokers showed dose-related trends toward decreased accuracy and increased response time on cognitive tests, with the authors concluding: "These data do not support the hypothesis that nicotine enhances cognitive functioning in non-smokers" 8
• A 1990 study found nicotine improved performance only in smokers (likely reversing withdrawal), but found no drug effects in nonsmokers 9

The baseball player study you mention is not included in the evidence provided, but the available research shows no consistent performance benefit in nicotine-naive individuals.

Safety Concerns Specific to Nonsmokers

The 1998 guidelines note that when healthy nonsmokers accidentally chew 4 mg nicotine gum, they experience nausea, dizziness, and anxiety more prominently than cardiovascular upset 4. The 2025 guideline emphasizes that nicotine is the primary driver of cardiovascular risk in tobacco products 7, and a 2024 study, while showing some EPC increases, used only 4.2 mg/day (much lower than your proposed doses) 10.

Clinical Bottom Line

There is no legitimate medical indication for prescribing or recommending nicotine gum or patches to healthy nonsmokers. The cardiovascular effects are stress responses, not benefits. The performance data show no enhancement in nonsmokers. The products are designed, tested, and approved exclusively for smoking cessation in current smokers 2, 3.

Common Pitfalls to Avoid

1. Misinterpreting cardiovascular safety data: Studies showing NRT is safe in smokers with cardiovascular disease 1, 11 do not translate to "cardiovascular benefits" in healthy nonsmokers—they simply show NRT is safer than continued smoking
2. Confusing withdrawal reversal with enhancement: Performance improvements seen in smokers using NRT reflect reversal of nicotine withdrawal, not true cognitive enhancement 9
3. Ignoring off-label liability: Recommending NRT to nonsmokers contradicts FDA labeling and all published guidelines, creating significant medicolegal exposure

What to Tell Patients

If a healthy nonsmoker asks about using nicotine for performance or cardiovascular benefits, the appropriate response is: "These products are designed only for people trying to quit smoking. In nonsmokers, nicotine causes cardiovascular stress—increased heart rate, blood pressure, and reduced heart rate variability—which are harmful, not beneficial. There is no evidence that nicotine improves performance in people who don't smoke. I cannot recommend or prescribe these products for your intended use."